Global Anti-Obesity Drugs Market 2017-2023

Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023

Anti-obesity drugs include all pharmacological treatments intended to reduce or control weight. Anti-obesity drugs are medically prescribed only in cases of morbid obesity, where weight loss is life-saving. An anti-obesity drug therapy is prescribed for a maximum of 12 weeks in the first instance. Thereafter weight loss is measured. Most of the time, the drug treatment is stopped where the obese patients do not achieve a 5% weight reduction after 12 weeks of drug treatment.

The market has been expanding at a significant pace in recent years. With the obvious driving factor being the worldwide surge in obesity levels, strong pipeline of anti-obesity drugs, and advanced medical research by drug-manufacturing companies. North America accounted for the largest market share in the Anti-Obesity Drugs market in 2016, and is expected to retain its dominance throughout the forecast period due to high level of awareness, favorable reimbursement policies, and increased involvement of government as well as non-government organizations in generating awareness and funding research. Europe is the second biggest market globally. The Asia Pacific market is anticipated to witness increasing CAGR due to the rise in obese population and improving healthcare infrastructure. Few of the prominent players in the market are Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., F. Hoffmann-La Roche AG, Vivus Inc., and Alizyme Inc.

The report provides the complete details of various market trends and adoption rate in various segments and across the regions. The major trends, drivers, restraints, and opportunities in each segment are also covered. This study will help stakeholders to understand the current and future market outlook to focus/expand/invest in the Anti-Obesity Drugs market.

This report also provides the competitive landscape of the leading players in Global Anti-Obesity Drugs market and this study will help the vendors to understand about their competitor’s landscape. The report can also be tailored as per the specific info required by the users. The customization of the report is available based on countries, vendor profiles, enterprise and vertical wise.

Report Scope:

Healthcare Category: PHARMACEUTICALS

Type by Mechanism

  • Peripherally Acting Anti-Obesity Drugs
  • Centrally Acting Anti-Obesity Drugs


  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities

Request for TOC at

Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Secondary & Primary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting


Market related information is congregated from both secondary and primary sources. Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

For more details on Research Methodology kindly click here to Engage with our Analyst.

Category :







Enquiry Hours